Cystatin C: A step forward in assessing kidney function and cardiovascular risk

Heart Failure Reviews

Volumn 17, Issue 2, 2012, Pages 251-261

  Lassus, Johan ^a   Harjola, Veli Pekka ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cardiorenal syndrome; Cystatin C; Heart failure; Prognosis; Renal function; Risk marker

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY FUNCTION; MORTALITY; PREDICTION; PROGNOSIS; SURVIVAL;

ACUTE KIDNEY INJURY; BIOLOGICAL MARKERS; CARDIO-RENAL SYNDROME; CARDIOVASCULAR DISEASES; CYSTATIN C; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; PROGNOSIS; RISK FACTORS;

EID: 84861860930     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9242-6     Document Type: Article

References (97)

1. Ronco C, McCullough P, Anker SD et al (2010) Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31(6): 703-711
2. Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4): 247-254
3. Laterza OF, Price CP, Cystatin ScottMG (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48(5): 699-707
4. Seronie-Vivien S, Delanaye P, Pieroni L et al (2008) Cystatin C: current position and future prospects. Clin Chem Lab Med 46(12): 1664-1686
5. Newman DJ (2002) Cystatin C. Ann Clin Biochem 39(Pt 2): 89-104
6. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A (2005) Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 38(1): 1-8
7. Simonsen O, Grubb A, Thysell H (1985) The blood serum concentrationof cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 45(2): 97-101
8. Knight EL, Verhave JC, Spiegelman D et al (2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65(4): 1416-1421
9. Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J (2008) Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 51(3): 385-394
10. Kilic T, Oner G, Ural E et al (2009) Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 207(2): 552-558
11. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C (2003) Impact of thyroid dysfunction on serum cystatin C. Kidney Int 63(5): 1944-1947
12. Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES (2003) Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem 49(4): 680-681
13. den Hollander JG, Wulkan RW, Mantel MJ, Berghout A (2003) Iscystatin C a marker of glomerular filtration rate in thyroid dysfunction? Clin Chem 49(9): 1558-1559
14. Risch L, Herklotz R, Blumberg A, Huber AR (2001) Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 47(11): 2055-2059
15. Bjarnadottir M, Grubb A, Olafsson I (1995) Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest 55(7): 617-623
16. Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F (2002) Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron 91(1): 13-20
17. Keller CR, Odden MC, Fried LF et al (2007) Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 71(3): 239-244
18. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG (2007) Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant 22(4): 1087-1092
19. Stenvinkel P, Ketteler M, Johnson RJ et al (2005) IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67(4): 1216-1233
20. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 74(111): S4-S9
21. Stevens LA, Schmid CH, Greene T et al (2009) Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 75(6): 652-660
22. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS (2006) Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 69(2): 399-405
23. Newman DJ, Thakkar H, EdwardsRGet al (1995) Serum cystatinC measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47(1): 312-318
24. Kyhse-Andersen J, Schmidt C, Nordin G et al (1994) Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40(10): 1921-1926
25. Hoek FJ, Kemperman FA, Krediet RT (2003) A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18(10): 2024-2031
26. Harmoinen A, Lehtimaki T, Korpela M, Turjanmaa V, Saha H (2003) Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clin Chem 49(7): 1223-1225
27. Coll E, Botey A, Alvarez L et al (2000) Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 36(1): 29-34
28. Pucci L, Triscornia S, Lucchesi D et al (2007) Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 53(3): 480-488
29. Macisaac RJ, Tsalamandris C, ThomasMC et al (2006) Estimating glomerular filtration rate in diabetes: a comparison of cystatin-Cand creatinine-based methods. Diabetologia 49(7): 1686-1689
30. Spanaus KS, Kollerits B, Ritz E et al (2010) Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem 56(5): 740-749
31. Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40(2): 221-226
32. Roos JF, Doust J, Tett SE, Kirkpatrick CM (2007) Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a metaanalysis. Clin Biochem 40(5-6): 383-391
33. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC (2002) Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 25(11): 2004-2009
34. Cherney DZ, Sochett EB, Dekker MG, Perkins BA (2010) Ability of cystatin C to detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated Type 1 diabetes. Diabet Med 27(12): 1358-1365
35. Huang SH, Sharma AP, Yasin A, Lindsay RM, Clark WF, FillerG (2011) Hyperfiltration affects accuracy of creatinine eGFR measurement. Clin J Am Soc Nephrol 6(2): 274-280
36. Ognibene A, Mannucci E, Caldini A et al (2006) Cystatin C reference values and aging. Clin Biochem 39(6): 658-661
37. Odden MC, Tager IB, Gansevoort RT et al (2010) Age and cystatin C in healthy adults: a collaborative study. Nephrol Dial Transplant 25(2): 463-469
38. Weinert LS, Prates AB, do Amaral FB, Vaccaro MZ, Camargo JL, Silveiro SP (2010) Gender does not influence cystatin C concentrations in healthy volunteers. Clin Chem Lab Med 48(3): 405-408
39. Herget-Rosenthal S, Marggraf G, Husing J et al (2004) Early detection of acute renal failure by serum cystatin C. Kidney Int 66(3): 1115-1122
40. Grubb A, Nyman U, Bjork J et al (2005) Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 51(8): 1420-1431
41. Stevens LA, Coresh J, Schmid CH et al (2008) Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3, 418 individuals with CKD. Am J Kidney Dis 51(3): 395-406
42. Macdonald J, Marcora S, Jibani M et al (2006) GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 48(5): 712-719
43. Ma YC, Zuo L, Chen JH et al (2007) Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int 72(12): 1535-1542
44. Madero M, Sarnak MJ, Stevens LA (2006) Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens 15(6): 610-616
45. Eriksen BO, Mathisen UD, Melsom T et al (2010) Cystatin C is not a better estimator of GFR than plasma creatinine in the general population. Kidney Int 78(12): 1305-1311
46. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K (2004) Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C.J Intern Med 256(1): 70-78
47. O'Riordan SE, Webb MC, Stowe HJ et al (2003) Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 40(Pt 6): 648-655
48. Fliser D, Ritz E (2001) Serum cystatin C concentration as amarker of renal dysfunction in the elderly. Am J Kidney Dis 37(1): 79-83
49. Perkins BA, Nelson RG, Ostrander BE et al (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 16(5): 1404-1412
50. Shlipak MG, Praught ML, Sarnak MJ (2006) Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 15(3): 270-275
51. Haase-Fielitz A, Bellomo R, Devarajan P et al (2009) Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery-a prospective cohort study. Crit Care Med 37(2): 553-560
52. Nejat M, Pickering JW, Walker RJ, Endre ZH (2010) Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant 25(10): 3283-3289
53. Ristikankare A, Poyhia R, Kuitunen A et al (2010) Serum cystatin C in elderly cardiac surgery patients. Ann Thorac Surg 89(3): 689-694
54. Bell M, Granath F, Martensson J et al (2009) Cystatin C is correlated with mortality in patients with and without acute kidney injury. Nephrol Dial Transplant 24(10): 3096-3102
55. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute dialysis quality initiative workgroup. Acute renal failure- definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 8(4): R204-R212
56. Mehta RL, Kellum JA, Shah SV et al (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2): R31
57. Villa P, Jimenez M, Soriano MC, Manzanares J, Casasnovas P (2005) Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care 9(2): R139-R143
58. Perianayagam MC, Seabra VF, Tighiouart H, Liangos O, Jaber BL (2009) Serum cystatin C for prediction of dialysis requirement or death in acute kidney injury: a comparative study. Am J Kidney Dis 54(6): 1025-1033
59. Wald R, Liangos O, Perianayagam MC et al (2010) Plasma cystatin C and acute kidney injury after cardiopulmonary bypass. Clin J Am Soc Nephrol 5(8): 1373-1379
60. Soto K, Coelho S, Rodrigues B et al (2010) Cystatin C as a marker of acute kidney injury in the emergency department. Clin J Am Soc Nephrol 5(10): 1745-1754
61. Lassus JP, Nieminen MS, Peuhkurinen K et al (2010) Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 31(22): 2791-2798
62. Briguori C, Visconti G, Rivera NV et al (2010) Cystatin C and contrast-induced acute kidney injury. Circulation 121(19): 2117-2122
63. Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Malyszko JS, Dobrzycki S (2009) Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail 31(10): 910-919
64. Waikar SS, Betensky RA, Bonventre JV (2009) Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant 24(11): 3263-3265
65. Premaratne E, MacIsaac RJ, Finch S, Panagiotopoulos S, Ekinci E, Jerums G (2008) Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care 31(5): 971-973
66. Hossain MA, Emara M, El Moselhi H, Shoker A (2009) Comparing measures of cystatin C in human sera by three methods. Am J Nephrol 29(5): 381-391
67. Grubb A, Blirup-Jensen S, Lindstrom V et al (2010) First certified reference material for cystatin C in human serum ERM-DA471/ IFCC. Clin Chem Lab Med 48(11): 1619-1621
68. Shlipak MG, Sarnak MJ, Katz R et al (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352(20): 2049-2060
69. Shlipak MG, Wassel Fyr CL, Chertow GM et al (2006) Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 17(1): 254-261
70. Deo R, Fyr CL, Fried LF et al (2008) Kidney dysfunction and fatal cardiovascular disease-an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J 155(1): 62-68
71. Shlipak MG, Katz R, Sarnak MJ et al (2006) Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145(4): 237-246
72. Ix JH, Shlipak MG, Chertow GM, Whooley MA (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the heart and soul study. Circulation 115(2): 173-179
73. Koenig W, Twardella D, Brenner H, Rothenbacher D (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51(2): 321-327
74. Keller T, Messow CM, Lubos E et al (2009) Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J 30(3): 314-320
75. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME (2008) Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 102(1): 54-57
76. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L (2004) Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 110(16): 2342-2348
77. Windhausen F, Hirsch A, Fischer J et al (2009) Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem 55(6): 1118-1125
78. Sarnak MJ, Katz R, Stehman-Breen CO et al (2005) Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 142(7): 497-505
79. Djousse L, Kurth T, Gaziano JM (2008) Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 155(1): 82-86
80. Moran A, Katz R, Smith NL et al (2008) Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail 14(1): 19-26
81. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA (2006) Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail 12(8): 601-607
82. Moran A, Katz R, Jenny NS et al (2008) Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis 52(5): 839-848
83. Patel PC, Ayers CR, Murphy SA et al (2009) Association of cystatin C with left ventricular structure and function: the Dallas heart study. Circ Heart Fail 2(2): 98-104
84. Tang WH, Van Lente F, Shrestha K et al (2008) Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail 14(5): 394-399
85. Arimoto T, Takeishi Y, Niizeki T et al (2005) Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Card Fail 11(8): 595-601
86. Shlipak MG, Katz R, Fried LF et al (2005) Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 45(2): 268-271
87. Alehagen U, Dahlstrom U, Lindahl TL (2009) Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail 11(4): 354-360
88. Lassus J, Harjola VP, Sund R et al (2007) Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28(15): 1841-1847
89. Campbell CY, Clarke W, Park H, Haq N, Barone BB, Brotman DJ (2009) Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol 104(3): 389-392
90. Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-Oton MD et al (2009) Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol 103(12): 1753-1759
91. Naruse H, Ishii J, Kawai T et al (2009) Cystatin C in acute heart failure without advanced renal impairment. Am J Med 122(6): 566-573
92. Luc G, Bard JM, Lesueur C et al (2006) Plasma cystatin-C and development of coronary heart disease: the PRIME study. Atherosclerosis 185(2): 375-380
93. Wu CK, Lin JW, Caffrey JL, Chang MH, Hwang JJ, Lin YS (2010) Cystatin C and long-term mortality among subjects with normal creatinine-based estimated glomerular filtration rates: NHANES III (Third National Health and Nutrition Examination Survey). J Am Coll Cardiol 56(23): 1930-1936
94. Menon V, Shlipak MG, Wang X et al (2007) Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 147(1): 19-27
95. Shlipak MG, Katz R, Kestenbaum B et al (2009) Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am J Nephrol 30(3): 171-178
96. Rifkin DE, Shlipak MG, Katz R et al (2008) Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 168(20): 2212-2218
97. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL Current and novel renal biomarkers in heart failure (under review)